Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Jeffrey P. Nadler"'
Autor:
Cimoch Pj, Douglas J. Ward, Johan Vingerhoets, Stephen M. Smith, Voorspoels E, Charles B. Hicks, Brian Woodfall, Richard M. W. Hoetelmans, Daniel S Berger, Gary Blick, Greenberg Rn, Jeffrey P. Nadler, Anthony Mills, Melanie A. Thompson, Cohen Cj, Schrader, Monika Peeters, Jayaweera Ds, Peter Ruane, P. Shalit, Steinhart Cr, Iveson Kj
Publikováno v:
AIDS. 21:F1-F10
OBJECTIVE TMC125-C223 is an open-label, partially blinded, randomized clinical trial to evaluate the efficacy and safety of two dosages of etravirine (TMC125), a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type a
Autor:
Michael C. Phillips, Jeffrey P. Nadler
Publikováno v:
Current Infectious Disease Reports. 7:221-226
Since the introduction of zidovudine 18 years ago, the treatment of HIV has been rapidly evolving. Current therapies target the HIV retrovirus successfully but contain their own perils. Active therapies with reduced adverse effects and long-term acti
Autor:
Richard A. Petruschke, Jeffrey P. Nadler, Harold P. Katner, Helene M. Wilson, David P. Paar, Tyler S. Finn, Robert K. Zeldin, Erin Jensen
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 31:483-487
There is no standard treatment of HIV-infected patients who fail protease inhibitor (PI)-containing antiretroviral therapy. This open-label, noncomparative 24-week study with a 24-week extension evaluated the efficacy, safety, and tolerability of twi
Autor:
Karen C. West, Vikas M. Virkud, Landis K. Crockett, Robert G. Brooks, Asim A. Jani, Spencer Lieb, Jeffrey P. Nadler, Richard S. Hopkins, Daniel R. Thompson, Gayle McLaughlin, Thomas M. Liberti
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 30:351-358
Background After markedly decreasing for 3 years, HIV/AIDS mortality declined only slightly in 1999. Methods The authors conducted a case-control study in four Florida urban public health HIV clinics to evaluate modifiable factors associated with HIV
Autor:
Susan Hunt, Calvin J. Cohen, Jeffrey P. Nadler, Allan Stein, Martin Markowitz, Neil M.H. Graham, Douglas L. Mayers, Steven Davis, Shannon Schrader, W. Keith Henry, Charles Farthing, Michael Sension, Stephen Brown, Werner Verbiest, Kurt Hertogs, Deborah Copeland, Harold A. Kessler, Richard Stryker, Melanie A. Thompson, Michael S. Saag, Michael H. Ames, Carol L. Brosgart, Gabriel Torres, Susan Jacobson, Jeffrey Goodgame, Howard Grossman, Marcus A. Conant, Ann C. Collier, Alex R. Rinehart, Jeffrey Galpin, Roberto C. Arduino
Publikováno v:
AIDS. 16:579-588
Objective To compare the effect of treatment decisions guided by phenotypic resistance testing (PRT) or standard of care (SOC) on short-term virological response. Design A prospective, randomized, controlled clinical trial conducted in 25 university
Autor:
Bienvenido G. Yangco, Jeffrey P. Nadler, Daniel O. Haight, Peter R. Pavan, L. David Ormerod, Scott M. Friedman, Curtis A. Margo, John T. Sinnott, Robert M. Schwartz, Matthew M. Menosky, Julie A. Larkin
Publikováno v:
Clinical Infectious Diseases. 26:34-45
Eleven patients with rapidly progressive herpetic retinal necrosis (RPHRN) complicating AIDS were investigated retrospectively to study the disease spectrum, systemic involvement, and therapy. The mean CD4 cell count was 24/microL. There was a charac
Autor:
Mark A. Brown, Jeffrey P. Nadler
Publikováno v:
Cancer Control. 3:544-551
The 15th year of the human immunodeficiency virus (HIV) epidemic is upon us. During this time we have seen the onslaught of secondary infections that has made HIV the number one killer of persons 25 to 44 years of age in the United States? Within the
Autor:
Jeffrey P. Nadler
Publikováno v:
Clinical Infectious Diseases. 23:227-230
In this AIDS Commentary, Dr. Nadler provides a rationale for early initiation of antiretroviral therapy in patients infected with human immunodeficiency virus (HIV). Although no definitive clinical trials have been published that are relevant to the
Autor:
Robert W. Shafer, Philip M. Grant, Jeffrey P. Nadler, Robert D. Harrington, Andrew R. Zolopa, Dale J. Kempf, Trevor Hawkins, Calvin J. Cohen, Andrea De Luca, Eric C. Wong, Richard A. Rode
Publikováno v:
Università degli Studi di Siena-IRIS
Several genotypic interpretation scores have been proposed for the evaluation of susceptibility to lopinavir/ritonavir (LPV/r) but have not been compared using an independent data set. This study was a retrospective multicenter cohort of patients ini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e487f316c0bfe602b52ac4eee70326d4
http://hdl.handle.net/11365/1011741
http://hdl.handle.net/11365/1011741
Autor:
Michael S. Saag, Timothy J. Wilkin, Gerald Pierone, Daniel S Berger, Jeffrey P. Nadler, Philippe Chiliade, Amy E. Colson, Eric Lefebvre, Joel E. Gallant, Marcus A. Conant, Ben van Baelen, Richard Haubrich
Publikováno v:
AIDS (London, England). 21(6)
BACKGROUND Agents for the treatment of HIV-1-infected patients with resistance to current antiretroviral (ART) drugs are needed. METHODS TMC114-C202 was a randomized, partially blinded, dose-finding study in treatment-experienced HIV-1-infected patie